Search
Sparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnSparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. … DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UsePoloxamer 188
go.drugbank.com/drugs/DB11333ApprovedP188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217]. … Due to its sufactant properties, P188 may also be found in over-the-counter (OTC) products such as toothpaste, laxatives and mouthwash, and used in various cosmetic, industrial and pharmaceutical applications
Categories: Compounds used in a research, industrial, or household settingCyproterone acetate
go.drugbank.com/drugs/DB04839ApprovedInvestigationalIt is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. … An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties.
Categories: Hormonal Contraceptives for Systemic Use, Contraceptive Agents, MaleSynonyms: Cyproterone 17-O-acetateChlorquinaldol
go.drugbank.com/drugs/DB13306Approved[F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. … Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]
Telaprevir
go.drugbank.com/drugs/DB05521ApprovedWithdrawnApproved in May 2011 by the FDA, Incivek was indicated for the treatment of HCV genotype 1 in combination with [DB00811], [DB00008], and [DB00022] [FDA Label]. … The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs [A19593].
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseSynonyms: (1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamideNadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigational[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and … Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.
Categories: Antihypertensive Agents Indicated for Hypertension, Beta Blocking Agents, Non-SelectiveProducts: NADOLOL MK 80 MG TABLETASSelumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials … [A193611] "The novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform
Oxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigationalOxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000. … [A186011] Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing
Products: Oxtellar XR, KALLION XRPrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Categories: Drugs for ConstipationCalcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalIt is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients.
Mixtures: HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETLİ ŞİŞE, HEPASELAMİN AMİNOASİT IV İNFÜZYON ÇÖZELTİSİ 500 ML SETSİZ ŞİŞE